BioCardia (NASDAQ:BCDA) Shares Down 5.5% – Should You Sell?

BioCardia, Inc. (NASDAQ:BCDA) fell 5.5% on Thursday. The company traded as low as $0.92 and last traded at $0.9287. 50,039 shares were traded during trading, a decline of 66% from the average daily volume of 146,650 shares. The stock had previously closed at $0.9824.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on BCDA shares. Wall Street Zen upgraded shares of BioCardia from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Zacks Research upgraded BioCardia from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 11th. HC Wainwright reaffirmed a “buy” rating on shares of BioCardia in a research report on Monday, August 24th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioCardia in a research report on Thursday, October 15th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $25.00.

BioCardia Trading Down 0.8%

The company has a market cap of $13.94 million, a P/E ratio of -1.44 and a beta of 0.62. The stock’s 50 day moving average is $1.06 and its 200-day moving average is $1.02.

BioCardia (NASDAQ:BCDA) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.05. As a group, sell-side analysts forecast that BioCardia, Inc. will post -0.71 EPS for the current year.

BioCardia Company Profile

BioCardia, Inc is a biotechnology company focused on developing regenerative cell therapies and related delivery systems for cardiovascular diseases. The company’s programs are designed to repair or improve heart tissue and function in patients with conditions such as chronic heart failure and refractory angina caused by coronary artery disease.

BioCardia’s lead programs include CardiAMP Cell Therapy, an investigational autologous treatment that uses a patient’s own bone marrow-derived cells, and CardiALLO, an investigational allogeneic cell therapy based on donor-derived cells.